V 2023

Development Safety Update Report 2023 BLINA-CELL

ŠÁLEK, Cyril

Basic information

Original name

Development Safety Update Report 2023 BLINA-CELL

Name in Czech

Development Safety Update Report 2023 BLINA-CELL

Authors

ŠÁLEK, Cyril

Edition

NA. Praha, 14 pp. NA, 2023

Publisher

ÚHKT PRAHA

Other information

Language

English

Type of outcome

Výzkumná zpráva

Field of Study

30230 Other clinical medicine subjects

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Organization unit

Faculty of Medicine

Keywords (in Czech)

blinatumomab; high-dose chemotherapy; acute lymphoblastic leukemia

Keywords in English

blinatumomab; high-dose chemotherapy; acute lymphoblastic leukemia

Tags

Tags

International impact
Změněno: 16/1/2024 10:16, Bc. Hana Vladíková, BBA

Abstract

V originále

Eudra CT 2017-004577-14, Blina-Cell, NCT04554485: Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults. (Principal Investigator: doc. MUDr. Mgr. Cyril Šálek, Ph.D., cyril.salek@uhkt.cz). Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults.

Links

90249, large research infrastructures
Name: CZECRIN IV